MedTrace Logo

Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma

NCT01748175 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 715

Last updated 2022-09-16

No results posted yet for this study

Summary

The Severe Asthma Research Program III is an NIH cooperative agreement involving 7 clinical centers that encompass a multidisciplinary partnerships between asthma clinician-scientists and scientists with expertise in immunology, pulmonary physiology, molecular genetics, molecular phenotyping, imaging, and bioinformatics. These clinical centers will jointly recruit volunteers with asthma for an observational longitudinal follow-up study. However, centers will also conduct specific mechanistic research projects at each participating institution. The University of Pittsburgh's SARP III study will determine the molecular and clinical stability of asthma phenotypes over time.

Conditions

  • Asthma
  • Severe Persistent Asthma

Interventions

DRUG

Triamcinolone Acetonide

Each subject that meets inclusion/exclusion criteria will receive triamcinolone acetonide intramuscularly at the end of visit 2. Adults ≥18 years will receive 40 mg triamcinolone acetonide. Children 6-17 years will receive 1 mg/kg triamcinolone acetonide (up to 40 mg maximum). Triamcinolone acetonide will be administered as a single intramuscular dose deep in the gluteal region

Sponsors & Collaborators

  • Sally E. Wenzel MD

    lead OTHER

Principal Investigators

  • Sally E Wenzel, MD · University of Pittsburgh

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2021-12-31
Completion
2022-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01748175 on ClinicalTrials.gov